Abstract
Leukemia is a life-threatening malignant tumor of the hematopoietic system. Currently, the main treatment modalities are chemotherapy and hematopoietic stem cell transplantation. However, increased drug resistance due to decreased sensitivity of leukemia cells to chemotherapeutic drugs presents a major challenge in current treatments. Autophagy-associated proteins involved in autophagy initiation have now been shown to be involved in the development of various types of leukemia cells and are associated with drug resistance. Therefore, this review explores the roles of autophagy-related proteins involved in four key autophagic processes: induction of autophagy and phagophore formation, phagophore extension, and autophagosome formation, on the development of various types of leukemias as well as drug resistance. Autophagy may become a promising therapeutic target for treating leukemia.
Introduction
While advancements in chemotherapy and stem cell transplantation have significantly improved outcomes for leukemia patients, drug resistance remains a formidable obstacle. For instance, while Acute Promyelocytic Leukemia (APL) boasts high cure rates, other subtypes like Acute Myeloid Leukemia (AML) see cure rates of only 35%–40% in younger patients, with even lower success in older populations.
Recent research identifies autophagy—the cell's internal recycling system—as a primary mechanism for this resistance. In healthy cells, autophagy serves as a housekeeping process to remove metabolic waste. However, leukemia cells hijack this pathway to survive the stress of chemotherapy, recycling damaged components to provide energy and avoid apoptosis (programmed cell death). This review synthesizes findings from over 100 recent studies to map how specific autophagy-related (ATG) proteins act as "survival switches" in leukemia.
The Autophagy Pathway in Leukemia
The autophagy process is a complex, multi-stage cascade. By categorizing this process into four distinct stages, researchers can better identify therapeutic targets to re-sensitize cancer cells to standard treatments.
- Induction: Triggered by the ULK1 complex and inhibited by mTORC1.
- Phagophore Formation: Involving Beclin-1 and the PI3K Class III complex.
- Phagophore Extension: Driven by the ATG12–ATG5–ATG16L1 system and LC3-II conjugation.
- Autophagosome Formation: Finalized by proteins like ATG9, leading to fusion with the lysosome.
Key Proteins and Clinical Implications
Specific proteins within the autophagy pathway serve as critical nodes for leukemia cell survival and drug resistance across various clinical subtypes, including AML, ALL, CLL, and CML.
- ULK1 as a Master Regulator: ULK1 is a primary initiator of autophagy. In AML, inhibiting ULK1 has been shown to re-sensitize cells to Daunorubicin (DNR) by preventing cells from repairing chemotherapy-induced damage.
- mTORC1 and Metabolic Control: mTORC1 typically inhibits autophagy under nutrient-rich conditions. In Acute Lymphoblastic Leukemia (ALL), upregulated mTORC1 activity is linked to therapy resistance, as it promotes cell growth while modulating the autophagy threshold.
- TIGAR and Metabolic Hijacking: The protein TIGAR acts as a bridge between metabolism and autophagy. By reducing oxidative stress (ROS), it effectively shields leukemia cells from the toxic effects of chemotherapy, particularly in AML.
- The BCR-ABL Connection: In Chronic Myelogenous Leukemia (CML), Beclin-1 interacts directly with the BCR-ABL oncogene, creating a feedback loop that promotes both cancer growth and tolerance to Tyrosine Kinase Inhibitors (TKIs) like Imatinib.
Mechanisms of Drug Resistance and Key Results
The review highlights several protein-specific impacts observed in both in vitro and in vivo models:
- ATG7 & ATG5: Knocking down these proteins in AML models significantly increases sensitivity to Cytarabine and improves overall survival in animal models.
- p62/SQSTM1: This protein links autophagy to the ubiquitin-proteasome system. Its accumulation activates survival pathways that impact proliferation in AML and CLL.
- MicroRNA Regulation: Specific microRNAs, such as miR-143 and miR-145, can downregulate ATG proteins, offering a potential gene-therapy route to overcoming resistance.
Limitations and Future Directions
Despite the promise of targeting autophagy, several hurdles remain. Autophagy is a "double-edged sword"; while it usually promotes resistance, in some cases (like APL treated with bortezomib), inducing autophagy can actually enhance a drug's effect. Furthermore, because healthy cells rely on autophagy for survival, the primary challenge is developing precision medicines that can inhibit autophagy specifically in leukemia cells to avoid systemic toxicity.
Future research must focus on the nuanced, context-dependent roles of these proteins to move from laboratory models to safe, targeted human therapies.
Summary updated